CYP46A1 and Alzheimer disease: Together, our data indicate CE as a dual upstream regulator of pTau and Aβ, and we propose CE-reduction, particularly through CYP46A1 activation, as a therapeutic approach to independently reduce accumulation of pTau and Aβ in AD patients.